Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
operative surgical procedures | D013514 |
Brand Name | Status | Last Update |
---|---|---|
dabigatran | ANDA | 2025-04-09 |
dabigatran etexilate | ANDA | 2025-05-15 |
pradaxa | New Drug Application | 2024-04-03 |
Expiration | Code | ||
---|---|---|---|
DABIGATRAN ETEXILATE MESYLATE, PRADAXA, BOEHRINGER INGELHEIM | |||
2024-12-21 | PED | ||
2024-06-21 | I-862, NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 4 | 3 | 13 | 27 | 47 |
Thromboembolism | D013923 | — | — | — | 9 | 11 | 3 | 8 | 31 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 8 | 8 | 1 | 5 | 22 |
Thrombosis | D013927 | — | — | — | 2 | 1 | 2 | 1 | 6 |
Renal insufficiency | D051437 | — | N19 | 3 | — | — | 2 | — | 5 |
Replacement arthroplasty | D019643 | — | — | — | — | — | 1 | 3 | 4 |
Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | 2 | — | 3 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | 1 | — | 2 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 1 | 2 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | 4 | — | 3 | 8 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 2 | — | 2 | 5 |
Replacement arthroplasty knee | D019645 | — | — | — | 1 | 2 | — | — | 3 |
Secondary prevention | D055502 | — | — | — | — | 2 | — | — | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 2 | — | — | 2 |
Replacement arthroplasty hip | D019644 | — | — | — | — | 1 | — | 1 | 2 |
Hematoma | D006406 | EFO_0010680 | — | — | — | 1 | — | — | 1 |
Embolic stroke | D000083262 | — | — | — | — | 1 | — | — | 1 |
Percutaneous coronary intervention | D062645 | — | — | — | — | 1 | — | — | 1 |
Intracranial sinus thrombosis | D012851 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Coronary disease | D003327 | — | — | — | 1 | — | — | 1 | 2 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | — | 1 |
Cardiac catheterization | D006328 | — | — | — | 1 | — | — | — | 1 |
Heart valve prosthesis | D006350 | EFO_0003906 | — | — | 1 | — | — | — | 1 |
Venous thrombosis | D020246 | — | I82.40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 53 | — | — | — | — | 53 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Blood coagulation tests | D001780 | — | — | — | — | — | — | 1 | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
Hemostatic disorders | D020141 | — | — | — | — | — | — | 1 | 1 |
Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Recreational drug use | D000084783 | — | — | — | — | — | — | 1 | 1 |
Drug tolerance | D004361 | — | — | — | — | — | — | 1 | 1 |
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | — | — | 1 | 1 |
Drug common name | Dabigatran |
INN | dabigatran |
Description | Dabigatran is an aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. It has a role as an anticoagulant, an EC 3.4.21.5 (thrombin) inhibitor and an EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor. It is an aromatic amide, a member of benzimidazoles, a carboxamidine, a member of pyridines and a beta-alanine derivative. |
Classification | Small molecule |
Drug class | thrombin inhibitors (argatroban type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21 |
PDB | — |
CAS-ID | 211914-51-1 |
RxCUI | — |
ChEMBL ID | CHEMBL48361 |
ChEBI ID | 70752 |
PubChem CID | 216210 |
DrugBank | DB14726 |
UNII ID | I0VM4M70GC (ChemIDplus, GSRS) |